publication date: Mar. 30, 2017
Chronic Myeloid Leukemia NEJM publishes long-term results of Gleevec for 1,106 patients worldwide
The New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.
According to the NCI, prior to Gleevec’s 2001 FDA approval, fewer than 1 in 3 CML patients survived five years past diagnosis. Brian Druker, who led the original clinical development of Gleevec, co-authored the study. The worldwide study enrolled 1,106 participants at 177 cancer centers in more than 16 countries.
“The long-term success of this treatment confirms the remarkable success we’ve seen since the very first Gleevec trials,” said Druker, director of the OHSU Knight Cancer Institute, a Howard Hughes Medical Institute Investigator and JELD-WEN Chair of Leukemia Research in the OHSU School of Medicine. “This study reinforces the notion that we can create effective and non-toxic therapies.”
The discovery of Gleevec ushered in the era of personalized cancer medicine, proving it was possible to shut down cells that enable cancer to grow without harming healthy ones.
In an accompanying editorial, “Imatinib Changed Everything,” Dan Longo, professor of medicine, Harvard Medical School; and deputy editor, the New England Journal of Medicine, wrote: “The development of imatinib fundamentally altered the field of oncology. Priorities shifted from agents that were active on dividing cells to understanding the … Continue reading CCL March 2017 – NEJM publishes long-term results of Gleevec for 1,106 patients worldwide
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.